Ranking History
Headlines
- Some Stocks We Like
Jul 02, 2008 08:33 AM
- Osiris Therapeutics to Present at the Jefferies Second Annual Healthcare Conference and Invitrogen Partners With International Regulome Consortium to Advance Stem Cell Research for the Development of Life Saving Therapies
Jun 19, 2008 09:29 AM
- Analyst Comments for Eli Lilly, Berkshire Hathaway, Celanese, Iconix Brand, Dassault, Osiris Therapeutics, Anglo American
Jun 11, 2008 06:47 PM
- Biotech Stocks: Opportunities abound for Osiris Therapeutics
May 27, 2008 05:23 PM
- Analyst Comments: iPass, Cytori Therapeutics, KT Corp., RH Donnelly, Osiris Therapeutics
May 12, 2008 11:25 AM
- NASDAQ Technical Picture - Narrow Range Inside Bar
May 09, 2008 02:54 AM
- Osiris Announces First Quarter 2008 Financial Results Conference Call and Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
May 06, 2008 08:59 AM
- Analyst Comments: Alpharma, Osiris Therapeutics, O2Micro, Community Health, Nash Finch, Regeneron, Salesforce.com, Avici Systems, URS Corp, Arena Pharma, Quality Systems, Dell
Feb 29, 2008 03:30 PM
- StemCells Inc.: Time to Play the Election
Feb 07, 2008 01:50 AM
- Jobs Report
Jan 04, 2008 10:29 AM
- NuVasive Completes Acquisition of Osteocel Biologics Business
Jul 24, 2008 04:43 PM
- Osiris Therapeutics Closes Osteocel Transaction Worth up to $137 Million
Jul 24, 2008 04:39 PM
- Osiris Therapeutics Announces $2 Million Milestone Payment for Clinical Progress of a Stem Cell Therapy for Type 1 Diabetes
Jun 25, 2008 07:08 AM
- Osiris Therapeutics to Present at the Jefferies Second Annual Healthcare Conference
Jun 18, 2008 06:09 PM
- Osiris Therapeutics to Present at the Piper Jaffray Europe Conference
Jun 18, 2008 06:08 PM
- Osiris Therapeutics to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
Jun 09, 2008 06:45 PM
- Osiris Therapeutics to Present at the Canaccord Adams Diabetes and Obesity Conference
Jun 03, 2008 07:11 AM
- Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Chronic Obstructive Pulmonary Disease
May 21, 2008 07:01 AM
- Osiris Therapeutics Reports First Quarter 2008 Financial Results
May 09, 2008 07:04 AM
- Osiris and NuVasive Enter into Definitive Agreement for Osteocel(R)
May 08, 2008 04:41 PM
- Four Biotechs on the Speculative Side
Jul 15, 2008 12:33 PM
- Thursday's Winners & Losers: Thornburg Mortgage
Feb 28, 2008 04:36 PM
- Osiris Therapeutics Posts Wider Q4 Loss On Costs OSIR
Feb 28, 2008 07:46 AM
- Osiris Therapeutics Q4 Loss Widens - Quick Facts OSIR
Feb 28, 2008 03:46 AM
- Osiris Therapeutics Gets FDA Approval To Conduct Phase II Study Of Prochymalin For Heart Attack Patients OSIR
Feb 26, 2008 08:05 AM
- Osiris Therapeutics To Receive $500K Milestone Payment From JCR Pharmaceuticals OSIR
Jan 07, 2008 09:46 AM
- 'Fast Money' Recap: Worst Start since 1932
Jan 04, 2008 09:41 PM
- Friday's Healthcare Winners & Losers
Jan 04, 2008 08:49 PM
- Drug stocks slide; Osiris jumps on Defense Dept. contract
Jan 04, 2008 10:58 AM
- Out of the Gate: Osiris Therapeutics (AP)
Jan 04, 2008 10:12 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
OSIR
|
Compare to S&P
|
| YTD |
25.21 %
|
39.63 %
|
| 4 Weeks |
20.98 %
|
24.51 %
|
| 12 Weeks |
25.63 %
|
36.83 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -7.14 %
|
|
EPS Growth in Last Year: -42.86 %
|
|
Sales Growth in Last Quarter: -93.95 %
|
|
Sales Growth in Last Quarter: -81.90 %
|
|
|
